Indaptus Therapeutics’ (INDP) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP) in a research note published on Monday, Benzinga reports. They currently have a $12.00 price objective on the stock.

Indaptus Therapeutics Trading Down 4.3 %

INDP stock opened at $2.65 on Monday. Indaptus Therapeutics has a 1 year low of $1.56 and a 1 year high of $4.08. The company has a fifty day simple moving average of $2.09 and a 200 day simple moving average of $2.10. The firm has a market cap of $22.63 million, a PE ratio of -1.44 and a beta of 1.28.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. As a group, analysts forecast that Indaptus Therapeutics will post -1.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of INDP. Vanguard Group Inc. raised its holdings in Indaptus Therapeutics by 18.7% in the 1st quarter. Vanguard Group Inc. now owns 242,235 shares of the company’s stock worth $969,000 after acquiring an additional 38,216 shares during the period. Renaissance Technologies LLC bought a new position in shares of Indaptus Therapeutics during the 2nd quarter worth about $51,000. State Street Corp bought a new position in shares of Indaptus Therapeutics during the 1st quarter worth about $78,000. Citadel Advisors LLC bought a new position in shares of Indaptus Therapeutics during the 4th quarter worth about $29,000. Finally, Northern Trust Corp bought a new position in shares of Indaptus Therapeutics during the 1st quarter worth about $41,000. Institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial.